AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
AstraZeneca chief executive Pascal Soriot ... Imfinzi (durvalumab), PARP inhibitor Lynparza (olaparib), and Calquence (acalabrutinib) for leukaemia. Daiichi Sankyo-partnered HER2 drug Enhertu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback